Robert Landewé
University of Amsterdam
22 Papers
70 Citations
Robert Landewé is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Medicine & Psoriatic arthritis. The author has an hindex of 9, co-authored 22 publications. Previous affiliations of Robert Landewé include Maastricht University.
Chat about Author
Papers
EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2.
Robert Landewé,Pedro Machado,Féline P B Kroon,Hans W J Bijlsma,Gerd R Burmester,Loreto Carmona,Bernard Combe,Massimo Galli,Laure Gossec,Annamaria Iagnocco,John D. Isaacs,Xavier Mariette,Iain B. McInnes,Ulf Mueller-Ladner,Peter J. M. Openshaw,Josef S Smolen,Tanja Stamm,Dieter Wiek,Hendrik Schulze-Koops +18 more
TL;DR: The provisional EULAR recommendations address several aspects of severe acute respiratory syndrome coronavirus 2, the virus, and the disease caused by SARS-CoV-2, COVID-19 and are meant for patients with rheumatic and musculoskeletal diseases (RMD) and their caregivers.
264
EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria
Désirée van der Heijde,Annette H M van der Helm-van Mil,Daniel Aletaha,Clifton O. Bingham,Gerd Burmester,Maxime Dougados,Paul Emery,David T. Felson,David T. Felson,Rachel Knevel,Tore K Kvien,Robert Landewé,Cédric Lukas,Iain B. McInnes,Alan J. Silman,Josef S Smolen,Ewa Stanislawska-Biernat,Angela Zink,Bernard Combe +18 more
TL;DR: A highly specific definition for erosive disease has thus been formulated and focus on patients who did not otherwise fulfil the 2010 ACR/EULAR RA criteria (<6 points).
135
What is axial spondyloarthritis? A latent class and transition analysis in the SPACE and DESIR cohorts
Alexandre Sepriano,Alexandre Sepriano,Sofia Ramiro,Désirée van der Heijde,Floris A. van Gaalen,Pierre Hoonhout,Anna Molto,Alain Saraux,Roberta Ramonda,Maxime Dougados,Robert Landewé +10 more
TL;DR: It is questionable whether some patients with ‘axSpA at risk’ will ever develop axSpA, and it is suggested that 5-year transitions across classes were unlikely.
56
EULAR/EFORT recommendations for the diagnosis and initial management of patients with acute or recent onset swelling of the knee
Robert Landewé,Klaus-Peter Günther,Cédric Lukas,J. Braun,B. Combe,Philip G. Conaghan,Karsten Dreinhöfer,D Fritschy,J Getty,H. J. L. van der Heide,Tore K Kvien,Klaus P Machold,Carina Mihai,M Mosconi,Rob G H H Nelissen,Eliseo Pascual,Karel Pavelka,M Pileckyte,Wolfhart Puhl,Leonardo Punzi,W Rüther,M San-Julian,Cosimo Tudisco,Rene Westhovens,E Witso,D. van der Heijde +25 more
TL;DR: This is the first combined interdisciplinary project of rheumatologists and orthopaedic surgeons, successfully aiming at achieving consensus in the diagnosis and initial management of patients presenting with acute or recent onset swelling of the knee.
41
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y).
Robert Landewé,Lianne S. Gensler,Denis Poddubnyy,Proton Rahman,M. Hojnik,Xiaoqi Li,Soyi Liu Leage,David H. Adams,Hilde Carlier,Filip Van den Bosch +9 more
TL;DR: The COAST-Y study as discussed by the authors evaluated the effect of continuing versus withdrawing ixekizumab (IXE) in patients with axial spondyloarthritis who had achieved remission.
24